Press Releases
  Date Title View
ROCKVILLE, Md., July 20, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that Dr. Stefan Schwabe MD, PhD has joined the Company as Executive Vice President of Research and Development and Chief Medical Officer. In this role, Dr. Schwabe will be responsible for product development activities including Clinical, ...
Posted: Jul 20, 2012
ROCKVILLE, Md., July 13, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceuticals company, announced on June 26 that it received a tentative approval letter from the Food & Drug Administration (the "FDA") for Trokendi XR™, a once-daily extended release formulation of topiramate (formerly known as SPN-...
Posted: Jul 13, 2012
ROCKVILLE, Md., June 26, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceuticals company, received a tentative approval letter from the Food & Drug Administration (the "FDA") for Trokendi XR™, a once-daily extended release formulation of topiramate (formerly known as SPN-538). The letter states that ...
Posted: Jun 26, 2012
ROCKVILLE, Md., June 7, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported consolidated financial results for the first quarter of 2012, and provided an update on key accomplishments to date and expected milestones for 2012. "We are very excited to be a public company, a...
Posted: Jun 7, 2012
ROCKVILLE, Md., May 4, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) (the "Company"), today announced the closing of its initial public offering of 10,000,000 of its common stock at a price of $5.00 per share. The Company's shares are listed on The NASDAQ Global Market under the trading symbol "SUPN." After underwriting disc...
Posted: May 4, 2012
ROCKVILLE, Md., April 30, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) (the "Company") today announced the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The Company's shares are expected to begin trading on The NASDAQ Global Market on Tuesday, May 1, 2012 under the trading s...
Posted: Apr 30, 2012
Rockville, MD, January 6, 2012 — Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million. The sale of its TCD Royalty Subsidiary, which was established in April 2008 to securitize royalties that were generated by Sanctura XR® and Or...
Posted: Jan 6, 2012
Rockville, MD, November 28, 2011 — today announced the initiation of a Phase IIb U.S. clinical trial of its product candidate SPN-810 in the treatment of impulsive aggression in the setting of ADHD. The study is a multi-center randomized, double-blind, placebo controlled clinical trial in children 6 to 12 diagnos...
Posted: Nov 28, 2011
Rockville, MD, March 11, 2011 – Supernus Pharmaceuticals, Inc. today announced that its Phase IIa U.S. clinical trial of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability, and showed statistically significant median reductio...
Posted: Mar 11, 2011
Rockville, MD, July 13, 2010 – Supernus Pharmaceuticals Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN812 for the treatment of ADHD in adults. The trial is a proof-of-concept, randomized, double-blind, placebo-controlled study in healthy adults aged 18 to 64, i...
Posted: Jul 13, 2010
FirstPrevious
...
15
NextLast
= add release to Briefcase